Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARISOPRODOL vs EMVERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Treatment of trichuriasis (whipworm infection),Treatment of enterobiasis (pinworm infection),Treatment of ascariasis (roundworm infection),Treatment of hookworm infections (Ancylostoma duodenale and Necator americanus),Off-label: Treatment of capillariasis, toxocariasis, and other helminth infections
250-350 mg orally 3 times daily and at bedtime
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Primarily hepatic; metabolized by microsomal enzymes (CYP450) to major metabolite 2-aminomebendazole, which is less active; also undergoes further metabolism.
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
~90-95% bound to plasma proteins, primarily albumin.
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
~1-2 L/kg; indicates extensive tissue distribution.
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
Oral: ~22-40% due to first-pass metabolism; improved with food.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
No adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No adjustment for mild (Child-Pugh A) or moderate (Child-Pugh B) impairment. Avoid use in severe hepatic impairment (Child-Pugh C) due to increased risk of toxicity.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Children ≥2 years: 100 mg orally twice daily for 3 days. Children <2 years: safety not established; use only if potential benefit outweighs risk.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
No specific adjustment required; use standard adult dosing. Monitor for adverse effects due to potential age-related renal or hepatic decline.
None
None.
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
Risk of neutropenia and agranulocytosis, especially with high doses or prolonged use,May cause bone marrow suppression; monitor blood counts in prolonged therapy,Hepatotoxicity reported; use caution in hepatic impairment,Seizures have occurred, particularly in patients with history of seizures,Not recommended in pregnancy (pregnancy category C); embryotoxic and teratogenic in animals
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
Hypersensitivity to mebendazole or any component of the formulation,Absolute contraindication: Known hypersensitivity
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
No significant food interactions; absorption is enhanced by fatty foods but not required for efficacy in enterobiasis. Avoid alcohol due to potential hepatotoxicity.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed. Risk cannot be ruled out, especially in the first trimester.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
Excretion in human milk unknown. Caution should be exercised when administered to a nursing woman. M/P ratio not available.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
No dose adjustment is recommended solely due to pregnancy, as pharmacokinetic changes are not well characterized. Use standard dosing: mebendazole 100 mg twice daily for 3 days for pinworm (or single 100 mg dose). For other indications, follow standard protocols.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
EMVERM (mebendazole) is poorly absorbed systemically, making it ideal for intraluminal helminth infections. Administer with fatty meal to enhance absorption when systemic effect (e.g., for trichinosis) is desired. Avoid in pregnancy (FDA Category C). Tablets may be chewed, swallowed, or crushed. Monitor for rare agranulocytosis, especially with concurrent metronidazole or high doses.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
Take exactly as prescribed; a second course may be needed if reinfection occurs.,Tablets can be chewed, crushed, or swallowed whole with or without food.,Mebendazole works by preventing worms from absorbing sugar, causing their death.,Strict hand hygiene and laundering of bedding/clothing to prevent reinfection.,Treat all household members if pinworm outbreak; withhold treatment in pregnancy unless essential.,Notify provider if fever, sore throat, or unusual bleeding/bruising (agranulocytosis warning).
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARISOPRODOL vs EMVERM, answered by our medical review team.
CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. EMVERM is a Anthelmintic that works by Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARISOPRODOL and EMVERM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. The standard adult dose of EMVERM is: Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARISOPRODOL and EMVERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . EMVERM is classified as Category C. FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.